Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cotsiranib |
Synonyms | |
Therapy Description |
Cotsiranib (STP705) is a nanoparticle siRNA therapeutic targeting TGFB1 and COX2 that potentially inhibits tumor cell survival and invasiveness and increases apoptosis (Journal of Clinical Oncology 2019 37:15_suppl, e14652). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cotsiranib | STP-705|STP 705|Cutasil | Cotsiranib (STP705) is a nanoparticle siRNA therapeutic targeting TGFB1 and COX2 that potentially inhibits tumor cell survival and invasiveness and increases apoptosis (Journal of Clinical Oncology 2019 37:15_suppl, e14652). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04293679 | Phase Ib/II | Cotsiranib | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | Completed | USA | 0 |
NCT04844983 | Phase II | Cotsiranib | A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC | Completed | USA | 0 |
NCT04669808 | Phase II | Cotsiranib | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma | Completed | USA | 0 |
NCT04676633 | Phase I | Cotsiranib | Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Completed | USA | 0 |